Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

The Lancet Oncology

Volumn 19, Issue 11, 2018, Pages 1468-1479

  Barlesi, Fabrice ^a   Vansteenkiste, Johan ^b   Spigel, David ^c   Ishii, Hidenobu ^d   Garassino, Marina ^e   de Marinis, Filippo ^f   Özgüroğlu, Mustafa ^g   Szczesna, Aleksandra ^h   Polychronis, Andreas ⁱ   Uslu, Ruchan ^j   Krzakowski, Maciej ^k   Lee, Jong Seok ^l   Calabrò, Luana ^m   Arén Frontera, Osvaldo ⁿ   Ellers Lenz, Barbara ^o   Bajars, Marcis ^p   Ruisi, Mary ^p   Park, Keunchil ^q  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g ISTANBUL UNIVERSITY   (Turkey)

^h Regional Lung Diseases Hospital   (Poland)

ⁱ MOUNT VERNON CANCER CENTRE   (United Kingdom)

^j EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^k INSTITUTE OF ONCOLOGY   (Poland)

^l Seoul National University Bundang Hospital   (South Korea)

^m UNIVERSITY HOSPITAL OF SIENA   (Italy)

ⁿ Centro Investigación Clínica Bradford Hill ^*  (Chile)

^o MERCK KGAA   (Germany)

^p EMD SERONO INC   (United States)

^q Sungkyunkwan University School of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AVELUMAB; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; PARACETAMOL; PLATINUM; PROGRAMMED DEATH 1 RECEPTOR; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ADULT; ADVERSE EVENT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER STAGING; CONTROLLED STUDY; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DISEASE CONTROL; DISEASE EXACERBATION; DRUG SAFETY; END STAGE RENAL DISEASE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HAZARD RATIO; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOTHYROIDISM; INTERSTITIAL LUNG DISEASE; KIDNEY FUNCTION; LEUKOPENIA; LIFE EXPECTANCY; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; MYOCARDITIS; NEUTROPHIL COUNT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPTIC SHOCK; TREATMENT DURATION; VERY ELDERLY; CLINICAL TRIAL; IMMUNOLOGY; LUNG TUMOR; MORTALITY; PATHOLOGY; TIME FACTOR; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DOCETAXEL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TIME FACTORS; TREATMENT OUTCOME;

EID: 85057183840     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30673-9     Document Type: Article

References (27)

1. Kazandjian, D, Suzman, DL, Blumenthal, G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist 21 (2016), 634–642.
2. Sul, J, Blumenthal, GM, Jiang, X, He, K, Keegan, P, Pazdur, R, FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 21 (2016), 643–650.
3. Weinstock, C, Khozin, S, Suzman, D, et al. US Food and Drug Administration approval summary: atezolizumab for metastatic non-small cell lung cancer. Clin Cancer Res 23 (2017), 4534–4539.
4. Brahmer, J, Reckamp, KL, Baas, P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
5. Borghaei, H, Paz-Ares, L, Horn, L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
6. Herbst, RS, Baas, P, Kim, DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
7. Rittmeyer, A, Barlesi, F, Waterkamp, D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 (2017), 255–265.
8. Pai-Scherf, L, Blumenthal, GM, Li, H, et al. FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond. Oncologist 22 (2017), 1392–1399.
9. Antonia, SJ, Villegas, A, Daniel, D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377 (2017), 1919–1929.
10. Gulley, JL, Rajan, A, Spigel, DR, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol 18 (2017), 599–610.
11. Apolo, AB, Infante, JR, Balmanoukian, A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol 35 (2017), 2117–2124.
12. Chung, HC, Arkenau, H, Wyrwicz, L, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: analysis of safety and clinical activity. J Clin Oncol, 34(suppl), 2016 abstr 4009.
13. Disis, ML, Patel, M, Pant, S, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase 1b trial: safety and clinical activity. J Clin Oncol, 34(suppl), 2016 abstr 5533.
14. Gulley, J, Exposure–response and PD-L1 expression analysis of second-line avelumab in patients with advanced NSCLC: data from the JAVELIN Solid Tumor trial. J Clin Oncol, 35(suppl), 2017 abstract 9086.
15. Tsao, MS, Kerr, KM, Kockx, M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project. J Thorac Oncol 13 (2018), 1302–1311.
16. Feng, Z, Schlichting, M, Helwig, C, et al. Comparative study of two PD-L1 expression assays in patients with non-small cell lung cancer (NSCLC). J Clin Oncol, 35(suppl), 2017 abstr e20581.
17. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
18. Robins, JM, Finkelstein, DM, Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 56 (2000), 779–788.
19. Kawaguchi, T, Matsumura, A, Fukai, S, et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 5 (2010), 1001–1010.
20. Ou, SH, Ziogas, A, Zell, JA, Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status. J Thorac Oncol 4 (2009), 1083–1093.
21. Horn, L, Spigel, DR, Vokes, EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35 (2017), 3924–3933.
22. Fehrenbacher, L, von Pawel, J, Park, K, et al. Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer. J Thorac Oncol 13 (2018), 1156–1170.
23. Parra, ER, Behrens, C, Rodriguez-Canales, J, et al. Image analysis-based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients. Clin Cancer Res 22 (2016), 6278–6289.
24. Mazzaschi, G, Madeddu, D, Falco, A, et al. Low PD-1 expression in cytotoxic CD8+ tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value. Clin Cancer Res 24 (2018), 407–419.
25. Robinson, LA, Jaing, CJ, Pierce Campbell, C, et al. Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung. Br J Cancer 115 (2016), 497–504.
26. Karen, K, Infante, JR, Taylor, MH, et al. Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer 124 (2018), 2010–2017.
27. Fehrenbacher, L, Spira, A, Ballinger, M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.